Covered recipient · General Payments record
JHUMKA GHOSH-NARANG
Allopathic & Osteopathic Physicians Internal Medicine Nephrology
General Payments · PY2018–2024
$744.85
- Reported across 35 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $274.08 | 10 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Retrophin, Inc. | $69.09 | 3 |
| Amgen Inc. | $65.67 | 2 |
| Ardelyx, Inc. | $34.71 | 1 |
| GENZYME CORPORATION | $28.92 | 1 |
| GlaxoSmithKline, LLC. | $28.25 | 1 |
| ANI Pharmaceuticals, Inc. | $28.06 | 1 |
| Fresenius USA Marketing, Inc. | $19.38 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (10)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $32.13 | 03/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117260373 | CMS |
| Amgen Inc. | $33.54 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117260375 | CMS |
| ANI Pharmaceuticals, Inc. | $28.06 | 01/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1091145272 | CMS |
| Ardelyx, Inc. | $34.71 | 08/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146681897 | CMS |
| Fresenius USA Marketing, Inc. | $19.38 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154196712 | CMS |
| GENZYME CORPORATION | $28.92 | 06/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139945485 | CMS |
| GlaxoSmithKline, LLC. | $28.25 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116349776 | CMS |
| Travere Therapeutics, Inc. | $21.96 | 01/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1149931312 | CMS |
| Travere Therapeutics, Inc. | $33.18 | 02/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1149931316 | CMS |
| Travere Therapeutics, Inc. | $13.95 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1149931308 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.